Artículos por temáticas

Oral Tau Aggregation Inhibitor for Alzheimer's Disease: Design, Progress and Basis for Selection of the 16 mg/day Dose in a Phase 3, Randomized, Placebo-Controlled Trial of Hydromethylthionine Mesylate

Wischik CM, Bentham P, Gauthier S, Miller S, Kook K, Schelter BO.

J Prev Alzheimers Dis. 2022;9(4):780-790. doi: 10.14283/jpad.2022.63.

Effects of eszopiclone on sleep quality and cognitive function in elderly patients with Alzheimer's disease and sleep disorder: A randomized controlled trial

Huo S, Cheng L, Li S, Xu F.

Brain Behav. 2022 Feb;12(2):e2488. doi: 10.1002/brb3.2488. Epub 2022 Jan 18.

The Dose and Duration-dependent Association between Melatonin Treatment and Overall Cognition in Alzheimer's Dementia: A Network Meta- Analysis of Randomized Placebo-Controlled Trials

Tseng PT, Zeng BY, Chen YW, Yang CP, Su KP, Chen TY, Wu YC, Tu YK, Lin PY, Carvalho AF, Stubbs B, Matsuoka YJ, Li DJ, Liang CS, Hsu CW, Sun CK, Cheng YS, Yeh PY, Shiue YL.

Curr Neuropharmacol. 2022;20(10):1816-1833. doi: 10.2174/1570159X20666220420122322.

Roles of Gut Microbiota in Pathogenesis of Alzheimer's Disease and Therapeutic Effects of Chinese Medicine

Sun YX, Jiang XJ, Lu B, Gao Q, Chen YF, Wu DB, Zeng WY, Yang L, Li HH, Yu B.

Chin J Integr Med. 2022 Nov;28(11):1048-1056. doi: 10.1007/s11655-020-3274-5. Epub 2020 Sep 1.

Integrating music-based interventions with Gamma-frequency stimulation: Implications for healthy ageing

Tichko P, Kim JC, Large E, Loui P.

Eur J Neurosci. 2022 Jun;55(11-12):3303-3323. doi: 10.1111/ejn.15059. Epub 2020 Dec 6.

Accelerated Approval of Aducanumab: Where Do We Stand Now?

Barenholtz Levy H.

Ann Pharmacother. 2022 Jun;56(6):736-739. doi: 10.1177/10600280211050405. Epub 2021 Oct 1.

Formaldehyde toxicity in age-related neurological dementia

Kou Y, Zhao H, Cui D, Han H, Tong Z.

Ageing Res Rev. 2022 Jan;73:101512. doi: 10.1016/j.arr.2021.101512. Epub 2021 Nov 17.

Of education and public policy: Aducanumab

Lundebjerg NE, Hollmann PA, Supiano MA.

J Am Geriatr Soc. 2022 Jan;70(1):81-84. doi: 10.1111/jgs.17523. Epub 2021 Nov 3.

Low Dose Lithium Treatment of Behavioral Complications in Alzheimer's Disease: Lit-AD Randomized Clinical Trial

Devanand DP, Crocco E, Forester BP, Husain MM, Lee S, Vahia IV, Andrews H, Simon-Pearson L, Imran N, Luca L, Huey ED, Deliyannides DA, Pelton GH.

Am J Geriatr Psychiatry. 2022 Jan;30(1):32-42. doi: 10.1016/j.jagp.2021.04.014. Epub 2021 May 12.

Advancements and future directions in research of the roles of insulin in amyloid diseases

Miller Y.

Biophys Chem. 2022 Feb;281:106720. doi: 10.1016/j.bpc.2021.106720. Epub 2021 Nov 17.

Dietary and supplemental long-chain omega-3 fatty acids as moderators of cognitive impairment and Alzheimer's disease

Wood AHR, Chappell HF, Zulyniak MA.

Eur J Nutr. 2022 Mar;61(2):589-604. doi: 10.1007/s00394-021-02655-4. Epub 2021 Aug 15.

An alarm on vitamin D therapy for Alzheimer's disease patients: a case with Alzheimer's disease whose symptoms were exacerbated under chronic use of eldecalcitol

Nakajima-Ohyama KC, Tansho K, Tanimukai H.

Psychogeriatrics. 2022 Jan;22(1):145-148. doi: 10.1111/psyg.12786. Epub 2021 Nov 10.

Effects of Exercise in the Treatment of Alzheimer's Disease: An Umbrella Review of Systematic Reviews and Meta-Analyses

Andrade A, Siqueira TC, D'Oliveira A, Dominski FH.

J Aging Phys Act. 2022 Jun 1;30(3):535-551. doi: 10.1123/japa.2021-0033. Epub 2021 Sep 6.

Ameliorative Effects of Phytomedicines on Alzheimer's Patients

Khandia R, Viswanathan N, Singhal S, Alqahtani T, Almikhlafi MA, Simonov AN, Ashraf GM.

Curr Alzheimer Res. 2022;19(6):420-439. doi: 10.2174/1567205019666220610155608.

Biomarker and therapeutic potential of peripheral extracellular vesicles in Alzheimer's disease

Vandendriessche C, Kapogiannis D, Vandenbroucke RE.

Adv Drug Deliv Rev. 2022 Nov;190:114486. doi: 10.1016/j.addr.2022.114486. Epub 2022 Aug 8.